123 related articles for article (PubMed ID: 9275430)
1. [Clinical study on immunotherapy of ovarian cancer with tumor infiltrating lymphocytes].
Hua Z; Lu J; Li H
Zhonghua Fu Chan Ke Za Zhi; 1996 Sep; 31(9):555-7. PubMed ID: 9275430
[TBL] [Abstract][Full Text] [Related]
2. Clinical and biological effects of intraperitoneal injections of recombinant interferon-gamma and recombinant interleukin 2 with or without tumor-infiltrating lymphocytes in patients with ovarian or peritoneal carcinoma.
Freedman RS; Kudelka AP; Kavanagh JJ; Verschraegen C; Edwards CL; Nash M; Levy L; Atkinson EN; Zhang HZ; Melichar B; Patenia R; Templin S; Scott W; Platsoucas CD
Clin Cancer Res; 2000 Jun; 6(6):2268-78. PubMed ID: 10873077
[TBL] [Abstract][Full Text] [Related]
3. Prolonged disease-free period in patients with advanced epithelial ovarian cancer after adoptive transfer of tumor-infiltrating lymphocytes.
Fujita K; Ikarashi H; Takakuwa K; Kodama S; Tokunaga A; Takahashi T; Tanaka K
Clin Cancer Res; 1995 May; 1(5):501-7. PubMed ID: 9816009
[TBL] [Abstract][Full Text] [Related]
4. Immunomodulation in patients with epithelial ovarian cancer after adoptive transfer of tumor-infiltrating lymphocytes.
Ikarashi H; Fujita K; Takakuwa K; Kodama S; Tokunaga A; Takahashi T; Tanaka K
Cancer Res; 1994 Jan; 54(1):190-6. PubMed ID: 8261438
[TBL] [Abstract][Full Text] [Related]
5. Interleukin-2 expanded lymphocytes from lymph node and tumor biopsies of human renal cell carcinoma, breast and ovarian cancer.
Bouet-Toussaint F; Genetel N; Rioux-Leclercq N; Bansard JY; Levêque J; Guillé F; Patard JJ; Lesimple T; Catros-Quemener V
Eur Cytokine Netw; 2000 Jun; 11(2):217-24. PubMed ID: 10903800
[TBL] [Abstract][Full Text] [Related]
6. [The comparison of biological characteristics between tumor-infiltrating lymphocytes and tumor-associated lymphocytes in ascites of epithelial ovarian carcinoma].
Kang S; Shen K; Lang J
Zhonghua Fu Chan Ke Za Zhi; 1998 Oct; 33(10):607-10. PubMed ID: 10806687
[TBL] [Abstract][Full Text] [Related]
7. Prognostic significance of CD3+ tumor-infiltrating lymphocytes in ovarian carcinoma.
Tomsová M; Melichar B; Sedláková I; Steiner I
Gynecol Oncol; 2008 Feb; 108(2):415-20. PubMed ID: 18037158
[TBL] [Abstract][Full Text] [Related]
8. Postoperative immunotherapy for patients with hepatocarcinoma using tumor-infiltrating lymphocytes.
Wang Y; Chen H; Wu M; Bao J; Cong W; Wang H
Chin Med J (Engl); 1997 Feb; 110(2):114-7. PubMed ID: 9594281
[TBL] [Abstract][Full Text] [Related]
9. Ex vivo expanded tumour-infiltrating lymphocytes from ovarian cancer patients release anti-tumour cytokines in response to autologous primary ovarian cancer cells.
Owens GL; Price MJ; Cheadle EJ; Hawkins RE; Gilham DE; Edmondson RJ
Cancer Immunol Immunother; 2018 Oct; 67(10):1519-1531. PubMed ID: 30039427
[TBL] [Abstract][Full Text] [Related]
10. Potential clinical application of tumor-infiltrating lymphocyte therapy for ovarian epithelial cancer prior or post-resistance to chemotherapy.
Sakellariou-Thompson D; Forget MA; Hinchcliff E; Celestino J; Hwu P; Jazaeri AA; Haymaker C; Bernatchez C
Cancer Immunol Immunother; 2019 Nov; 68(11):1747-1757. PubMed ID: 31602489
[TBL] [Abstract][Full Text] [Related]
11. Differential expression of CD3zeta message and protein in tumor infiltrating lymphocytes from solid tumor specimens and malignant ascites from patients with ovarian carcinoma.
Pappas J; Wolfson AD; Jung WJ; Oleszak EL; Helm CW; Freedman RS; Tsygankov AY; Platsoucas CD
Anticancer Res; 2009 Nov; 29(11):4673-82. PubMed ID: 20032419
[TBL] [Abstract][Full Text] [Related]
12. Tumor-infiltrating lymphocytes contain higher numbers of type 1 cytokine expressors and DR+ T cells compared with lymphocytes from tumor draining lymph nodes and peripheral blood in patients with cancer of the uterine cervix.
Santin AD; Ravaggi A; Bellone S; Pecorelli S; Cannon M; Parham GP; Hermonat PL
Gynecol Oncol; 2001 Jun; 81(3):424-32. PubMed ID: 11371133
[TBL] [Abstract][Full Text] [Related]
13. Immunosensitization of resistant human tumor cells to cytotoxicity by tumor infiltrating lymphocytes.
Frost P; Caliliw R; Belldegrun A; Bonavida B
Int J Oncol; 2003 Feb; 22(2):431-7. PubMed ID: 12527945
[TBL] [Abstract][Full Text] [Related]
14. Treatment Regimen, Surgical Outcome, and T-cell Differentiation Influence Prognostic Benefit of Tumor-Infiltrating Lymphocytes in High-Grade Serous Ovarian Cancer.
Wouters MC; Komdeur FL; Workel HH; Klip HG; Plat A; Kooi NM; Wisman GB; Mourits MJ; Arts HJ; Oonk MH; Yigit R; de Jong S; Melief CJ; Hollema H; Duiker EW; Daemen T; de Bruyn M; Nijman HW
Clin Cancer Res; 2016 Feb; 22(3):714-24. PubMed ID: 26384738
[TBL] [Abstract][Full Text] [Related]
15. Immunologic features of tumor-infiltrating lymphocytes and peripheral blood lymphocytes in ovarian cancer patients.
Schöndorf T; Engel H; Kurbacher CM; Brenne U; Kolhagen H; Göhring UJ; Scharl A; Mallmann P
J Soc Gynecol Investig; 1998; 5(2):102-7. PubMed ID: 9509389
[TBL] [Abstract][Full Text] [Related]
16. [Effects of auto-tumor infiltrating lymphocytes induced by interleukin (IL)-12 with IL-2 on patients of primary hepatic carcinoma].
Zhang YX; Wang XY; Liu JB; Zhang SQ; Chen YR
Zhonghua Yi Xue Za Zhi; 2008 Apr; 88(14):973-6. PubMed ID: 18756970
[TBL] [Abstract][Full Text] [Related]
17. [A new therapeutic concept in the treatment of metastatic cancers of the kidney: the TIL (tumor infiltrating lymphocytes)].
Peyret C
J Urol (Paris); 1991; 97(2):63-71. PubMed ID: 2071925
[TBL] [Abstract][Full Text] [Related]
18. Correlation between expression of cyclooxygenase-2 and the presence of CD4+ infiltrating T-lymphocyte in human primary hepatocellular carcinoma.
Gao YW; Chen YX; Wang ZM; Zhou LD; Li XY; Li LX; Luo QZ; Tian W; Fu CY; Zhou JH
Hepatogastroenterology; 2008; 55(82-83):345-50. PubMed ID: 18613363
[TBL] [Abstract][Full Text] [Related]
19. Efficient inhibition of intraperitoneal human ovarian cancer growth and prolonged survival by gene transfer of vesicular stomatitis virus matrix protein in nude mice.
Lin X; Chen X; Wei Y; Zhao J; Fan L; Wen Y; Wu H; Zhao X
Gynecol Oncol; 2007 Mar; 104(3):540-6. PubMed ID: 17112567
[TBL] [Abstract][Full Text] [Related]
20. [Study on the TIL and NK of IL-2 injected via pelvic retroperitoneal space in gynecological cancer patient].
Chen J; Cao ZY; Zhang P; Peng ZL; Yang YL; Bi JH
Sichuan Da Xue Xue Bao Yi Xue Ban; 2004 May; 35(3):406-8. PubMed ID: 15181850
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
